PLUS THERAPEUTICS, INC. — Director's Dealing 2016

Jun 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-06-15

Reporting Person: HEDRICK MARC H (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-15	Common Stock	X	41305	—	Acquired	44292	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-15	Subscription Rights (Right to Buy)	$2.55	X	41305	Disposed	2016-06-10	See Footnote (41305)	Indirect
2016-06-15	Warrants (Right to Buy)	$3.06	X	20652	Acquired	2018-12-14	Common Stock (20652)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38341	Direct
Common Stock	500	Indirect

Footnotes

F1: Shares held directly by M Hedrick & T Hedrick TTEE Dr. Marc Hamilton Hedrick & TRA U/A DTD 09/13/1999, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees.

F2: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55.

F3: Shares held directly in an IRA for the benefit of the Reporting Person, for which the Reporting Person is the sole beneficial owner.

F4: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.